These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines. Gurbuz AT; Elliott WG; Zia AA Eur J Cardiothorac Surg; 2005 Jan; 27(1):138-49. PubMed ID: 15621486 [TBL] [Abstract][Full Text] [Related]
63. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a. Almeida L; Neves M; Cardoso E; Melo A J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911 [TBL] [Abstract][Full Text] [Related]
64. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Schwid SR; Panitch HS Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202 [TBL] [Abstract][Full Text] [Related]
65. Severe septal panniculitis in a multiple sclerosis patient treated with interferon-beta. Mazzon E; Guarneri C; Giacoppo S; Rifici C; Tchernev G; Polimeni G; Wollina U Int J Immunopathol Pharmacol; 2014; 27(4):669-74. PubMed ID: 25572749 [TBL] [Abstract][Full Text] [Related]
66. Multiple sclerosis, interferon beta-1b and depression A prospective investigation. Feinstein A; O'Connor P; Feinstein K J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662 [TBL] [Abstract][Full Text] [Related]
67. Interferon beta-1b injection site reactions and necroses. Gaines AR; Varricchio F Mult Scler; 1998 Apr; 4(2):70-3. PubMed ID: 9599336 [TBL] [Abstract][Full Text] [Related]
68. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases? Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L; J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808 [TBL] [Abstract][Full Text] [Related]
69. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Bramanti P; Sessa E; Rifici C; D'Aleo G; Floridia D; Di Bella P; Lublin F Neurology; 1998 Dec; 51(6):1720-3. PubMed ID: 9855531 [TBL] [Abstract][Full Text] [Related]
70. Adherence to therapy: using an evidence-based protocol. Moore LA; Kaufman MD; Algozzine R; Irish N; Martin M; Posey CR Rehabil Nurs; 2007; 32(6):227-32. PubMed ID: 18065143 [TBL] [Abstract][Full Text] [Related]
71. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Tremlett HL; Oger J Mult Scler; 2004 Jun; 10(3):298-301. PubMed ID: 15222695 [TBL] [Abstract][Full Text] [Related]
72. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosis. Tremlett H Neurology; 2002 Jun; 58(12):1868. PubMed ID: 12084903 [No Abstract] [Full Text] [Related]
73. Morphea secondary to interferon beta1b injection: a case and review of the literature. Ozlu E; Karadag AS; Akdeniz N; Uzuncakmak TK; Zemheri E; Ozkanli S Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046913 [TBL] [Abstract][Full Text] [Related]
74. A case of cutaneous necrosis during interferon-beta 1b (B-IFN) therapy in multiple sclerosis. Albani C; Albani G J Neurol Neurosurg Psychiatry; 1997 Apr; 62(4):418. PubMed ID: 9120466 [No Abstract] [Full Text] [Related]